Menu
Search
|

Menu

Close
X

Pulmatrix Inc PULM.OQ (NASDAQ Stock Exchange Capital Market)

1.51 USD
+0.00 (+0.00%)
As of Mar 20
chart
Previous Close 1.51
Open --
Volume 2
3m Avg Volume 98,310
Today’s High --
Today’s Low --
52 Week High 12.00
52 Week Low 0.72
Shares Outstanding (mil) 8.03
Market Capitalization (mil) 12.12
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
1
EPS (USD)
FY18
-4.755
FY17
-9.267
FY16
-18.793
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.82
Price to Sales (TTM)
vs sector
79.23
9.06
Price to Book (MRQ)
vs sector
0.56
4.61
Price to Cash Flow (TTM)
vs sector
--
40.52
Total Debt to Equity (MRQ)
vs sector
0.00
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
13.95
Return on Investment (TTM)
vs sector
-163.06
12.09
Return on Equity (TTM)
vs sector
-163.29
13.20

EXECUTIVE LEADERSHIP

Mark Iwicki
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Robert Clarke
Chief Executive Officer, Director, Since 2015
Salary: $220,635.00
Bonus: $115,500.00
William Duke
Chief Financial Officer, Since 2015
Salary: $160,385.00
Bonus: $91,250.00
David Hava
Chief Scientific Officer, Since 2012
Salary: $163,327.00
Bonus: $64,125.00
Jean Sung
Vice President - Pharmaceutical Development, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

99 Hayden Ave Ste 390
LEXINGTON   MA   02421-7966

Phone: +1781.3572333

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

SPONSORED STORIES